BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

IOMED, Inc. (IOX) Reports Fourth Quarter Fiscal 2006 Results


8/29/2006 10:00:06 AM

SALT LAKE CITY, Aug. 29 /PRNewswire-FirstCall/ -- Iomed, Inc. today reported financial results for the fourth quarter and fiscal year ended June 30, 2006.

Fourth Quarter Results

For the quarter ended June 30, 2006, sales were $2,617,000 compared with $2,941,000 a year ago. The decreased sales were primarily due to reduced unit sales volume to certain large dealers. Gross margin improved to 63.2% in the fourth quarter versus 61.6% a year ago.

Selling, general and administrative (SG&A) expenses decreased 13% during the fourth quarter compared with a year ago due to reduced professional fees and lower personnel costs. Research and development expenses were higher than a year ago due to increased investment in new product development activities.

Iomed reported net income of $53,000, or $0.01 per diluted share, for the fourth quarter of fiscal 2006 compared with net income of $30,000, or nil per share, for the fourth quarter of fiscal 2005. Net income in the quarter benefited from net interest income of $90,000 compared to $51,000 in the prior year. Pursuant to new accounting rules, which became effective for the Company beginning this fiscal year, net income in the current period was affected by a non-cash charge of $34,000 in stock option related compensation expense.

Fiscal Year Results

For the fiscal year ended June 30, 2006, Iomed reported sales of $10,843,000, down 5% from a year ago. This decline was primarily due to the reduced unit sales volumes, which affected fourth quarter sales. Gross margin declined slightly to 60.6% from 61.6% during the comparable fiscal year.

SG&A expenses were down 9% during the fiscal year due to reduced personnel, professional fees and litigation-related expenses. Litigation-related expenses were $887,000 for the fiscal year of 2006 versus $971,000 a year ago.

Net income during fiscal 2006 was up 41% from a year ago. The Company reported net income of $600,000, or $0.08 per diluted share, compared with net income of $425,000, or $0.06 per diluted share, a year ago. Net income for the fiscal year benefited from increased net interest income from improved rates. Net income in the current fiscal year was negatively affected by a non-cash charge of $150,000 in stock option related compensation expense.

During fiscal year 2006, Iomed generated operating cash flow of $967,000. Working capital increased 4% to $9.4 million, long-term debt decreased 53% to $393,000 and total equity increased 10% to $10.8 million. Cash and cash equivalents were $8.4 million at June 30, 2006.

Management Comments

"Reduced unit sales volume was the major factor affecting our sales during the year," said Robert J. Lollini, President and CEO. "Lower sales to Compex Technologies, our second largest customer, reimbursement pressures and increased competition all contributed to this decline. The acquisition of Compex by Encore Medical Inc., the parent company of our largest competitor, will likely have a continuing effect on our sales in fiscal 2007. However, we are optimistic that our efforts to retain and service Compex's end-user customer accounts either directly or through alternative channels within our distributor network will be effective in reducing the impact on future periods," continued Mr. Lollini.

"During fiscal 2006, we continued to generate strong gross profit margins, generate cash, reduce debt and build equity, while increasing investment in new products that may enhance our competitive position as well as the competitive position of our distribution partners. We also settled two intellectual property lawsuits, limiting our potential exposure and future litigation-related expense," Mr. Lollini said.

Iomed is a leader in developing, manufacturing and marketing active drug delivery systems used primarily to treat acute local inflammation in the physical and occupational therapy and sports medicine markets. The Company is pursuing opportunities to advance its position as a provider of quality, innovative non-invasive medical products that improve patient healthcare. Iomed seeks to accomplish this by expanding its product line, distributing new products, developing strategic partnerships, and through acquisitions. To find out more about Iomed, Inc. , visit our website at www.iomed.com.

The statements contained in this news release that are not purely historical are forward-looking statements, as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and include Iomed's beliefs, expectations or intentions regarding its future operations and financial condition. All forward-looking statements included in this news release are made as of the date hereof and are based upon information available to Iomed as of such date. Iomed assumes no obligation to update any forward-looking statement. It is important to note that actual outcomes could differ materially from those in such forward-looking statements. Readers should also refer to the risk factors and other disclosures set forth in Iomed's filings with the Securities Exchange Commission, including Forms 10-K, 10-Q and 8-K.

-TABLES FOLLOW- INCOME STATEMENTS Three Months Ended Twelve Months Ended June 30, June 30, 2006 2005 2006 2005 (unaudited) (unaudited) Product sales $2,617,000 $2,941,000 $10,843,000 $11,426,000 Cost of products sold 963,000 1,129,000 4,277,000 4,401,000 Gross profit 1,654,000 1,812,000 6,566,000 7,025,000 Operating costs and expenses: Selling, general and administrative 1,362,000 1,566,000 5,171,000 5,703,000 Research and product development 329,000 267,000 1,101,000 993,000 Total operating costs and expenses 1,691,000 1,833,000 6,272,000 6,696,000 Operating income (loss) (37,000) (21,000) 294,000 329,000 Other income (expense): Interest expense (16,000) (23,000) (78,000) (121,000) Interest and other income, net 106,000 74,000 384,000 217,000 Net income $53,000 $30,000 $600,000 $425,000 Income per share: Basic $0.01 $0.00 $0.09 $0.06 Diluted $0.01 $0.00 $0.08 $0.06 Shares used in the computation of income per share: Basic 7,335,000 6,585,000 7,039,000 6,585,000 Diluted 7,886,000 7,666,000 7,910,000 7,665,000 CONDENSED BALANCE SHEETS June 30, June 30, 2006 2005 (unaudited) (audited) Cash and cash equivalents $8,426,000 $8,293,000 Working capital, net $9,418,000 $9,032,000 Restricted cash $275,000 $585,000 Total assets $12,673,000 $12,538,000 Long-term obligations $393,000 $836,000 Accumulated deficit $(31,132,000) $(31,732,000) Shareholders' equity $10,816,000 $9,868,000 STATEMENTS OF CASH FLOWS Twelve Months Ended June 30, 2006 2005 Cash flows from operating activities (unaudited) Net income $600,000 $425,000 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 381,000 550,000 Other non-cash charges 150,000 -- Changes in operating assets and liabilities: Accounts receivable 104,000 28,000 Inventories 14,000 (58,000) Prepaid expenses (1,000) (8,000) Trade accounts payable 66,000 (237,000) Other accrued liabilities (347,000) 442,000 Net cash provided by operating activities 967,000 1,142,000 Cash flows from investing activities Purchases of equipment and furniture (60,000) (61,000) Purchase of intangible assets (750,000) -- Net cash used in investing activities (810,000) (61,000) Cash flows from financing activities Change in restricted cash balance 310,000 477,000 Proceeds from issuance of common shares 198,000 -- Payments on long-term obligations (532,000) (603,000) Net cash used in financing activities (24,000) (126,000) Net increase in cash and cash equivalents 133,000 955,000 Cash and cash equivalents at beginning of period 8,293,000 7,338,000 Cash and cash equivalents at end of period $8,426,000 $8,293,000

Iomed, Inc.

CONTACT: Brian Mower, CFO, or Betsy Truax, Investor Relations Consultant,ext. 411, info@iomed.com, both of Iomed, Inc., +1-801-975-1191



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES